A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single Doses of ENV8058 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 22 Dec 2015
At a glance
- Drugs TAK 058 (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors Takeda
- 16 Dec 2015 Number of treatment arms changed from 6 to 7 with different doses of TAK 058 as reported by ClinicalTrials.gov.
- 20 Jan 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 19 Jun 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.